GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zivo Bioscience Inc (OTCPK:ZIVO) » Definitions » Return-on-Tangible-Asset

Zivo Bioscience (Zivo Bioscience) Return-on-Tangible-Asset : -745.19% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Zivo Bioscience Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Zivo Bioscience's annualized Net Income for the quarter that ended in Mar. 2024 was $-5.11 Mil. Zivo Bioscience's average total tangible assets for the quarter that ended in Mar. 2024 was $0.69 Mil. Therefore, Zivo Bioscience's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was -745.19%.

The historical rank and industry rank for Zivo Bioscience's Return-on-Tangible-Asset or its related term are showing as below:

ZIVO' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -6616   Med: -1687.16   Max: 153.9
Current: -666.7

During the past 13 years, Zivo Bioscience's highest Return-on-Tangible-Asset was 153.90%. The lowest was -6616.00%. And the median was -1687.16%.

ZIVO's Return-on-Tangible-Asset is ranked worse than
97.29% of 1552 companies
in the Biotechnology industry
Industry Median: -39.47 vs ZIVO: -666.70

Zivo Bioscience Return-on-Tangible-Asset Historical Data

The historical data trend for Zivo Bioscience's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zivo Bioscience Return-on-Tangible-Asset Chart

Zivo Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,947.50 -3,092.02 -190.14 -157.38 -580.59

Zivo Bioscience Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -485.51 -901.41 -519.20 -574.57 -745.19

Competitive Comparison of Zivo Bioscience's Return-on-Tangible-Asset

For the Biotechnology subindustry, Zivo Bioscience's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zivo Bioscience's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zivo Bioscience's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Zivo Bioscience's Return-on-Tangible-Asset falls into.



Zivo Bioscience Return-on-Tangible-Asset Calculation

Zivo Bioscience's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-7.777/( (2.123+0.556)/ 2 )
=-7.777/1.3395
=-580.59 %

Zivo Bioscience's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-5.112/( (0.556+0.816)/ 2 )
=-5.112/0.686
=-745.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


Zivo Bioscience  (OTCPK:ZIVO) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Zivo Bioscience Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Zivo Bioscience's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Zivo Bioscience (Zivo Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
21 East Long Lake Road, Suite 100, Bloomfield Hills, MI, USA, 48304
Zivo Bioscience Inc is a research and development company operating in both the biotech and agtech sectors, with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company's pipeline candidates are; Bovine Mastitis, Canine Joint Health, Human Immune Modulation, Human Food Ingredients, and Skin Health.
Executives
Alison A Cornell director 210 CARNEGIE CENTER, PRINCETON NJ 08540
Christopher D. Maggiore officer: CHIEF FINANCIAL OFFICER 4788 NOBLES POND DR. NW, CANTON OH 44718
Nola E Masterson director 768 WEST CALIFORNIA WAY, WOODSIDE CA 94062
John Bernard Payne director 9900 NE 114TH CIRCLE, VANCOUVER WA 98662
Strome Mezzanine Fund, Lp 10 percent owner 100 WILSHIRE BLVD., SUITE 1750, SANTA MONICA CA 90401
Keith Marchiando officer: Chief Financial Officer C/O ZIVO BIOSCIENCE, INC., 21 E. LONG LAKE ROAD, SUITE 100, BLOOMFIELD HILLS MI 48304
Mark E Strome 10 percent owner 100 WILSHIRE BLVD, 15TH FL, SANTA MONICA CA 90401
Strome Alpha Fund L P 10 percent owner 100 WILSHIRE BLVD SUITE 1750, SANTA MONICA CA 90401
Strome Investment Management Lp 10 percent owner 100 WILSHIRE BLVD, 15TH FLOOR, SANTA MONICA CA 90401
Strome Group, Inc. 10 percent owner 100 WILSHIRE BLVD., SUITE 1750, SANTA MONICA CA 90401
Hep Investments Llc 10 percent owner 2804 ORCHARD LAKE RD, STE 205, KEEGO HARBOR MI 48320
Rondeau Robert O Jr director 70 WEST LONG LAKE RD, STE 119, TROY MI 48098
Thomas Kevin Cox director 470 MICHGAMME LANE, LAKE FOREST IL 60045
Andrew A Dahl officer: President, CEO 7 WEST SQUARE LAKE ROAD, STE 6165, BLOOMFIELD HILLS MI 48302
Brian W Young other: See remarks below. 1800 NW CORPORATE BLVD, BOCA RATON FL 33431

Zivo Bioscience (Zivo Bioscience) Headlines

From GuruFocus

ZIVO Bioscience Announces Reverse Stock Split

By Business Wire 10-26-2023